Resmetirom (Rezdiffra – Madrigal), a thyroid hormone receptor-beta agonist, has received accelerated approval from the FDA for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis in adults. NASH has recently been renamed metabolic dysfunction-associated steatohepatitis (MASH). Resmetirom is the first drug to be approved in the US for this indication.

MASH — Nonalcoholic fatty liver disease (recently renamed metabolic dysfunction-associated steatotic liver disease [MASLD]) can progress to MASH, which is characterized by hepatic steatosis,...  Continue reading

Coming Soon
Bempedoic Acid (Nexletol) and Other Nonstatins for Lipid Lowering
Aprocitentan (Tryvio) for Treatment-Resistant Hypertension
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
Drugs for Head Lice